On Friday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $92.46 which represents a slight increase of $0.05 or 0.05% from the prior close of $92.41. The stock opened at $92 ...

The drug has been called a profound advancement in medicine but getting it to those who need it is a "missing piece in the ...

On the occasion of the 37th World AIDS Day, the Chinese Association of STD and AIDS Prevention and Control and China Youth ...

Venture capital group Abingworth is reportedly trying to raise up to $1.5 billion in investment funding to support biopharma ...

Emboldened by technological advances and a deeper knowledge of glioblastoma, Merck, Kazia Therapeutics, CorriXR Therapeutics ...

The twice-yearly shot was 100% effective in preventing HIV infections in a study of women, and recently results published show it worked nearly as well in men.

Gilead's new drug, lenacapavir, shows unprecedented success in HIV prevention, offering hope especially for marginalized ...

The Tampa Bay Times e-Newspaper is a digital replica of the printed paper seven days a week that is available to read on ...

I'm sometimes asked how I started in AIDS organizing. Although it’s hard to pin when it happened, I will always remember ...

The HIV vaccine space has seen dwindling research activity as drug manufacturers turn to PrEP therapies for preventive ...

Aids was first identified 40 years ago: these are the game changers that have revolutionised treatment – and the obstacles ...